Alpha DNA Investment Management’s Coursera COUR Stock Holding History

Alpha DNA Investment Management’s Portfolio COUR Stock Details COUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40,756	Closed	-$1.29M	–	112
2021 Q3	$1.29M	Buy	+40,756	New	+$1.53M	0.88%	92

Other funds holding COUR

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

KXA

KPCB XIV Associates Menlo Park, California $42.8M AUM 16.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Alpha DNA Investment Management's COUR Position: Q4 2021 in Review

Alpha DNA Investment Management sold out of Coursera (COUR) in Q4 2021, closing a stake of 40,756 shares — an estimated $1.29M sold.

Alpha DNA Investment Management first reported a position in COUR in Q3 2021 and held it in 1 quarter. The position peaked at $1.29M in Q3 2021. 176 funds tracked by Wall St. Rank hold COUR as of Q4 2021.

Alpha DNA Investment Management reported no remaining Coursera position as of Q4 2021 after selling out during the quarter.
Alpha DNA Investment Management sold 40,756 Coursera shares in Q4 2021, an estimated $1.29M.
Alpha DNA Investment Management first reported a position in Coursera in Q3 2021 and held it in 1 quarter.
Alpha DNA Investment Management's Coursera position peaked at $1.29M in Q3 2021.
176 funds tracked by Wall St. Rank held Coursera as of Q4 2021.

Based on Alpha DNA Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.